Novartis Cosentyx® Receives Positive CHMP Opinion for Non-Radiographic Axial Spondyloarthritis Treatment
source: pixabay.com

Novartis Cosentyx® Receives Positive CHMP Opinion for Non-Radiographic Axial Spondyloarthritis Treatment

  According to a press release on Global Newswire, Novartis has received a positive opinion on Cosentyx® from the Committee for Medicinal Products for Human Use (CHMP). This positive opinion…

Continue Reading Novartis Cosentyx® Receives Positive CHMP Opinion for Non-Radiographic Axial Spondyloarthritis Treatment

Post Mortem Gene Therapy Suggests Hopeful Results for Parkinson’s Disease Treatment

  Research findings can sometimes come from unexpected places. For example, according to Parkinson's News Today, the benefits and shortcomings of an investigative gene therapy were explored through the post-mortem analysis…

Continue Reading Post Mortem Gene Therapy Suggests Hopeful Results for Parkinson’s Disease Treatment
Exclusive Distribution Agreement in Turkey for ONPATTRO to Treat Hereditary ATTR Amyloidosis
Sourced from: Nephron / CC BY-SA (https://creativecommons.org/licenses/by-sa/3.0)

Exclusive Distribution Agreement in Turkey for ONPATTRO to Treat Hereditary ATTR Amyloidosis

  According to a press release from FirstWord Pharma, Gen and Alnylam Pharmaceuticals have signed an exclusive distribution deal in Turkey for RNAi therapeutic ONPATTRO. This therapy drug will treat…

Continue Reading Exclusive Distribution Agreement in Turkey for ONPATTRO to Treat Hereditary ATTR Amyloidosis